Airway hyperresponsiveness was recently described in patients with chronic cervical spinal cord injury (tetraplegia). The response was attributed to unopposed cholinergic broncho constrictor activity due to loss of sympathetic innervation of the airway. To determine if the administration of a cholinergic antagonist alters resting airway tone in these patients, ipratropium bromide (72 f.. lg) was administered by aerosol to 25 tetraplegic patients. We found that 12 of 25 patients (48%) had significant improvement (defined as � 12%) in forced expired volume in 1 s (FEV1) and/or forced vital capacity (FVC). A significant correlation between airway responsiveness and complaints of dyspnea at rest, completep;;ss of injury (sensory), or smoking history was not found. These findings of improved ?irflow after the use of an anticholinergic bronchodilator agent provides further evidence that transection of the cervical cord results in unopposed parasympathetic activity and a resultant increase in resting airway tone.
Introduction
It was recently reported that approximately 40% of otherwise healthy patients with tetraplegia undergoing routine pulmonary function testing had a significant bronchodilator response (> 12%) following inhalation of a beta 2 agonist. 1 This finding suggested that many patients with cervical spinal cord injury have an obstructive ventilatory impairment, characterized by an increase in resting airway tone, in addition to the well described restrictive ventilatory defect. 2 -8 Further evid ence of ventilatory impairment comes from methacho line challenge testing, which demonstrated marked airway hyperresponsiveness in all patients with tetra plegia, a response which was completely blocked by pretreatment with the cholinergic antagonist ipratro pium bromide. 9 Based upon these findings, it was postulated that airway hyperresponsiveness in patients with tetraplegia represents a loss of modulatory sympathetic fibers, which originate in the upper six thoracic segments of the spinal cord; thus, broncho-constrictive cholinergic innervation, which arises in the vagal nuclei of the brainstem and passes down the vagus nerves to synapse in ganglia that are located in the walls of airway, would remain intact. 10
To further evaluate the apparent cholinergic hyper responsiveness in patients with tetraplegia we assessed pulmonary function parameters before and after the administration of ipratropium bromide to determine if the agent caused bronchodilation in this population.
Methods
Twenty-five male patients with tetraplegia were re cruited from the Spinal Cord Injury Service at the Veterans Affairs Medical Center, Bronx, New York.
The study group consisted of 10 current smokers and 15 non-smokers (defined as those who are ex-smokers with no cigarette use for 1 year or more, or a lifetime never smoker). Six patients had complete motor and sensory loss, 17 had complete motor and incomplete sensory loss, and two had incomplete motor and sensory loss. At the time of study, no subject displayed evidence of respiratory tract infections or other acute pulmonary symptoms, and none gave a history of asthma or allergies.
Pulmonary function testing was performed with the patients seated upright in their wheelchairs using a Sensor Medics dry rolling seal spirometer (Yorba Linda, CA analysis was used to determine differences in the frequency of responders versus non-responders for dyspnea (yes, no), completeness of injury (incomplete sensory, complete sensory), and smoking history (cur rent smokers, non-smokers).
Results
Characteristics of the study population including age, duration of injury, and smoking history are shown (Table 1) . Overall, 12 of 25 patients (48%) had a positive bronchodilator response. For the study group as a whole, the average FEV 1 and FVC were signifi cantly (P = 0.0036 and P = 0.0084, respectively) higher post-bronchodilator than pre-bronchodilator. Spirometry parameters for the responder and non responder groups before and after administration of ipratropium bromide for current smokers and non smokers are shown ( Table 2 ). In the smoking history subgroups, a significant bronchodilator response was seen in six of 10 (60%) current smokers and six of 15 (40%) non-smokers. x! analyses revealed no significant differences betwee, n the number of patients with dyspnea at rest, smoking history, or completeness of cord lesion, and the bronchodilator response to ipratro pium bromide ( Table 3 ).
Discussion
In this study, we found that approximately 50% of patients with tetraplegia had a positive bronchodilator response to 72 f.1.g of inhaled ipratropium bromide. The Although the results of the two studies were essentially the same, one difference was that the beta 2 agonist (metaproterenol) was given by a powered nebulizer (50 psi), whereas the anticholinergic (ipratropium bro mide) was given via a spacer device. In addition, the previous finding that eight of eight non-smoking patients with tetraplegia were hyperresponsive to in haled methacholine9 demonstrated that airway hyper reactivity is also present. A likely explanation for our previous findings 1, 9 is that transection of the cervical spinal cord disrupts sympathetic innervation of the lung, which originates in the upper six thoracic segments, thereby leaving intact parasympathetic (cholinergic) nerves, which arise in vagal nuclei in the brainstem and pass down the vagus nerve to synapse in ganglia situated in airway walls. 1 0, 1 5 As a result, cholinergic bronchoconstrictor activity is unopposed by bronchodilatory sympathetic fibers, which presumably interact with parasympathetic ganglia cells in the peribronchial plexa to modulate transmission of post-ganglionic parasympathetic fibers. The use of anticholinergic agents to treat diseases of the airway is based on their ability to compete with acetylcholine at muscarinic receptor sites. 2 0 These receptors have been demonstrated on airway smooth muscle cells and mucous cells, especially in submucosal glands. In human airways, different muscarinic sub types have been identified, which include M 1 receptors on sympathetic nerves and parasympathetic ganglia, M 2 receptors on cholinergic nerves (these receptors function as feedback inhibitory receptors), and M 3 receptors on airway smooth muscle. Since acetylcholine released from post-ganglionic parasympathetic nerve endings has been shown to contract smooth muscle , 1 5 antimuscarinic drugs act to reduce vagally mediated increases in bronchomotor tone. Our findings suggest that patients with tetraplegia may demonstrate physiological improvement in pul monary function with the use of a beta 2 agonist or an Bronchodilatory eff ects of ipratroplum bromide PL Almenoff et 01 anticholinergic agent. Although no detailed studies have been performed which evaluate the respiratory symptoms among patients with high spinal cord injury, in one survey, it was reported that 18% (seven of 39)
with complete lesions complained of chronic cough, 18% (seven of 39) of chronic sputum production, 24% (nine of 37) of persistent wheeze, and 50% (19 of 38) of any wheeze. 2 1 Also, since atelectasis and pneumonia are the major causes of morbidity and mortality in patients with spinal cord injury, 22 -2 5 it is conceivable that chronic inhalation of a beta 2 agonist or anticholin ergic agent may decrease the incidence of mucus retention and respiratory complications. A long term study would be required to determine if chronic use of bronchodilators benefits patients with spinal cord injury.
